bortezomib Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (3)

Phase 2 (2)
Phase 3 (1)

Interventional (3)

Chinese University of Hong Kong (1)
GlaxoSmithKline (1)
Henan Cancer Hospital (1)

No (3)

No (3)

Adult (18+) (3)
Pediatric (Under 18) (1)

I am/have/had

I am/have/hadmeasurable disease

I am/have/hadmultiple myeloma

I am/have/hadcancer

I am/have/hadrefractory multiple myeloma

I am/have/hadlymphoma

I am/have/hadleukemia

I am/have/hadflow cytometry

I am/have/hadmarginal zone lymphoma

I am/have/hadbortezomib/dexamethasone

I am/have/hadremission

I am/have/hadacute lymphoblastic leukemia

I am/have/hadprotein concentration

I am/have/hadrecurrent multiple myeloma

I am/have/hadhair thinning

I am/have/hadmalt

I am/have/hadcns involvement

I am/have/hadb-cell acute lymphoblastic leukemia

I am/have/hadhematopoietic stem cell transplantation

I am/have/hadleukemic cells

I am/have/hadtesticular

added new label for I am/have/had

I am looking for

I am looking forbortezomib

I am looking fordexamethasone

I am looking forrituximab

I am looking forproteasome inhibitor

I am looking forcyclophosphamide

I am looking fordaratumumab

I am looking forbelantamab mafodotin

I am looking forprednisone

I am looking forbortezomib injection

I am looking forpediatric

I am looking forepirubicin

added new label for I am looking for

Advanced Filters

Found 3 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Adding bortezomid during the consolidation:The very early or early bone marrow relapse has low remission rate. Previous case studies showed that Bortezomib, a proteasome inhibitor, may achieve remission in refractory ALL, 80% remission in B-ALL with combination of chemotherapy and bortezomib.

proteasome inhibitor

bortezomib injection

pediatric

rituximab

cns involvement

0 views
19 Feb, 2024

Evaluation of Efficacy and Safety of Belantamab Mafodotin Bortezomib and Dexamethasone Versus Daratumumab Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

bortezomib/dexamethasone

cancer

protein concentration

multiple myeloma

measurable disease

0 views
19 Feb, 2024

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

lymphoma

marginal zone lymphoma

malt

rituximab

epirubicin

0 views
19 Feb, 2024